NM will not receive enough remdesivir for every hospital to allow every eligible patient to be treated. Thus, the MAT recommends criteria to allocate remdesivir to hospital facilities and patients through an equitable, transparent and data-driven process, including the following treatment criteria for patient selection and treatment:
▪ Adult patients hospitalized for SARS-CoV-2 and requiring oxygen but are not yet intubated.
▪ Duration of illness has not shown to be critical.
▪ Treatment duration of 5 days highly recommended.
▪ Patients on high flow nasal cannula, noninvasive mechanical ventilation, intubation with mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at treatment onset should receive lower priority for treatment.

Download this resource